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Calcification and cardiovascular problems in renal failure. Ex-
traosseus calcification has plagued management of renal failure
since the beginning of hemodialysis, but the issue has largely
been neglected because the impact on survival was thought
to be limited. The recent recognition that hyperphosphatemia
is a strong predictor of all-cause mortality, and particularly
of cardiac mortality, has transformed the situation. Relatively
stringent, though difficult to implement, guidelines have been
proposed for the management of hyperphosphatemia. Impor-
tant recent insights document that, for different reasons, both
high and low turnover of bone disease increase the risk of vas-
cular calcifications. Vascular calcification impacts cardiac death
not only by complicating coronary atherosclerosis, but also by
increasing the stiffness of central arteries, impacting on heart
function (increased impedance, reduced coronary perfusion).
While in the past extraosseous calcification, including vascular
calcification, was thought to be a passive process resulting from
transgression of a critical Ca × P product, recent studies show
that the adverse effect of hyperphosphatemia is also mediated
by active processes (e.g., induction of “osteogenic” genetic pro-
grams), and is modulated by calcification inhibitors.
It has been known for a long time [1] that hyper-
phosphatemia is a feature of chronic renal failure which
causes extraosseous calcifications of soft tissues on the
one hand, and stimulates the parathyroid gland by pro-
moting parathyroid hormone (PTH) secretion and syn-
thesis [2, 3], as well as parathyroid cell proliferation
[4], on the other hand. This is true not only in patients
with renal disease. A close relation between phosphate
and hyperparathyroidism is also known in veterinar-
ian medicine [e.g., nutritional secondary hyperparathy-
roidism (“millers horse disease”) [5] and atrophic rhinitis
of swine (“Schnu¨ffelkrankheit”)] [6].
It is fair to say that in the past hyperphosphatemia
was considered by nephrologists not to be of prime im-
portance in the management of uremic patients because
direct consequences of hyperparathroidism are rarely a
cause of death. Such complacency was rudely shocked
when Block et al [7, 8] noted that predialytic serum phos-
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phate concentrations above 1.8 mmol/L were a powerful
predictor of all-cause mortality and, specifically, of mor-
tality from coronary artery disease. Initially, it had been
thought that the deleterious effect of hyperphosphatemia
on survival was entirely mediated by promotion of coro-
nary calcification, but more recent data (including our
own) have shown that the issues are more complex, and
both direct effects on cardiac structure [9, 10] (e.g., on
postcoronary microcirculation and on interstitial tissue),
and on central arteries (i.e., calcification of both media
and intimal plaques), are apparently involved [11]. Car-
diac fibrosis with and without calcification [12] affects left
ventricular (LV) compliance, and calcification of central
arteries increases impedance and, thus, LV stroke work
[13].
As a consequence, it has been recommended [14] that a
predialysis phosphate concentration of 5.5 mg/dL should
not be exceeded, and this is also reflected in the new
DOQI guidelines. It is difficult, however, to achieve this
goal. This can easily be understood if one considers the
P-balance in hemodialysis and peritoneal dialysis pa-
tients, respectively (Fig. 1) [15, 16]. With average mid-
European diets the intake of elemental phosphorous is
7000 mg/week, of which 50% to 70% (more so in patients
on active vitamin D) are absorbed (i.e., 4200 mg/week).
Three hemodialysis sessions will, on average, remove
800 mg per session, or 2400 mg/week [17], thus leav-
ing a difference of 1800 mg/week, which must be taken
care of by either reduction of dietary intake of P or by
the administration of P-binders. In peritoneal dialysis pa-
tients, around 300 to 400 mg phosphorus is removed per
daily peritoneal dialysis treatment, resulting in 2100 to
2800 mg phosphorus removed per week—thus, the net
phosphate balance is similar. The paradox of the low
removal of P by hemodialysis, despite its low molecu-
lar weight and adequate dialysance, is explained by the
fact that equilibration between intra- and extracellular
P represents the bottleneck if high efficiency dialysis
sessions are used [18]. Contraintuitively, long, slow dial-
ysis sessions remove more P so that paradoxically even
hypophosphatemia may be observed [19]
This dilemma necessitates that one has in principle ei-
ther to reduce the dietary intake of P or to administer
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Difference
Removal by PD
Hemodialytic removal ~ 800 mg/session 2400 mg/week
Intestinal absorption
(50-70%)
~ 600 mg/d 4200 mg/week
Diet ~ 1000 mg/d 7000 mg/week
~ 350 mg/day 2400 mg/week
1800 mg/week
Fig. 1. Phosphate balance in dialyzed pa-
tients.
oral phosphate binders. We strongly argue against major
dietary restrictions in view of the fact that malnutrition is
a considerable hazard in HD patients, as reflected by the
relation between survival and BMI [20], even in the range
of frank obesity [21]. Only food items with very high P
content should be limited or eliminated (e.g., dairy prod-
ucts or food items with added P, for example, sausages).
This leaves only administration of oral P-binders as the
major alternative. If possible, any administration today of
aluminium-containing salts should be avoided because
of the risks of osteomalacia, anemia, and encephalopa-
thy. The most frequently used P-binder today is calcium
carbonate (or calcium acetate) with meals, which carries
the risks of a positive calcium balance, hypercalcemic
episodes, and particularly promotes vascular calcifica-
tion. Although for obvious reasons prospective evidence
is not available, several retrospective studies [11, 22] show
the correlation between the cumulative calcium load and
vascular calcification.
Recently, novel P-binders have been introduced, par-
ticularly sevelamer, an exchange resin with lipid-lowering
properties that has been documented to halt progression
of coronary calcification [23], either because of effective
phosphate binding with concomitantly lower calcium in-
take or because of lower lipid concentrations. The lat-
ter point is important because Tamashiro [24] showed
by electron beam computed tomography (EBCT) that
coronary calcification and dyslipidemia are significantly
correlated.
The short-term observations with another novel phos-
phate binder, lanthanum carbonate, appear promising,
but the long-term safety of this compound remains still to
be established, even though efficacy and safety data over
an intermediate period of observation are encouraging, as
recently published in several pertinent communications
[25–27].
A completely novel approach to control of P may be
calcimimetics. In a controlled study, cinacalcet [28] low-
ered not only the PTH concentration but also serum P
and the Ca × P product.
It is of note that calcification is seen both in high and
low bone turnover disease for different reasons: with high
PTH, the egress of phosphate from bone is increased,
while in low bone turnover, the “sponge” function of
bone is diminished so that less P is sequestered in bone.
Consequently, arterial calcification and cardiovascular
mortality, respectively, appear to be related to both ex-
tremes of PTH dysregulation, as demonstrated recently
[29, 30].
MEDIATION OF THE CARDIOVASCULAR
EFFECTS OF HYPERPHOSPHATEMIA
It has been known for some time [31] that the coro-
nary plaques of uremic patients with coronary heart
disease are more heavily calcified than the plaques of
nonuremic patients with coronary heart disease (Fig.
2). It is important, however, that the risk of coronary
plaques is influenced by coronary remodelling. Fuessl
[32] found a higher prevalence of constrictive remod-
elling when plaques were calcified, while Schwarz et al
[31] found more prevalent eccentric remodelling. It is also
of note that unpublished studies in our laboratory showed
that the plaques of uremic patients with coronary heart
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Fig. 2. Comparison of calcified plaques in a nonuremic person and uremic patient. [Orcein (A + B) and EVG (C + D) staining; magnifica-
tion ×100]. I, intima; M, media. (A and C) Coronary plaque of a 60-year-old person with an atheromatous plaque with beginning calcification
(A, C →). (B and D) Fifty-nine–year-old uremic patient with marked calcification (→) of the intima and media.
disease had a more marked inflammatory character than
in nonuremic patients, as reflected by more marked ex-
pression of C5b-9, C-reactive protein (CRP) TGF-b , and
collagen IV around coronary plaques [abstract; Gross ML
et al, J Am Soc Nephrol 15:834A, 2004). This is in line with
in vivo observations of Oh [33], in which the coronary
calcium score in young dialysis patients was significantly
correlated with the CRP concentration. Interestingly, a
marked interaction was found between PTH and CRP
concentration. The latter is of interest because a num-
ber of studies in primary hyperparathyroidism [34, 35]
showed increased cardiovascular risk in primary hyper-
parathyroidism.
Since the seminal work of Braun and Luft [36], it is
known that coronary calcification by EBCT are highly
prevalent in renal patients [37, 38]. Accelerated coronary
calcification has been shown even in early renal disease;
Bursztyn [39] compared patients with creatinine clear-
ance > and <60 mL/per minute and measured coronary
calcification by EBCT. The increase in calcium score was
considered to be greater in the renal as compared to the
nonrenal patients.
In nonrenal patients it is known that coronary calcifica-
tion, exclusively reflecting intimal calcification, predicts
coronary events [40], but whether this is true for ure-
mic patients has long been uncertain. The recent work of
Matsuoka shows that the 5-year survival of patients with a
high coronary calcium score (>200) was 30% lower com-
pared to patients with a score <200, thus clearly estab-
lishing the prognostic relevance of coronary calcification
in dialyzed patients, as well [41]. This confirms previous
demonstrations of an inverse correlation between calcifi-
cation of central arteries and of cardiac valves on the one
hand, and survival of patients on dialysis on the other
hand [42, 43].
It is certainly not appropriate to assume that all the risk
to high phosphate is mediated via coronary calcification.
Amann et al showed that hyperphosphatemic uremic an-
imals on a high-phosphate diet compared to normophos-
phatemic uremic animals on a low-phosphate diet had
Ketteler et al: Hypertension and cardiovascular disease in progressive renal failure S-123
more interstitial fibrosis of the heart and microvascular
disease [10]. Finally, Guerin [11] found a relation between
aortic calcification and aortic stiffening. Although other
factors, particularly disruption of the architecture with
increase of collagen and loss of elastic fibers [44], marked
deposition of hydroxyapatite crystals on elastin fibers, as
documented by our recent studies, certainly aggravates
loss of elasticity. This will increase the cardiac workload
and decrease coronary perfusion. The former is due to
the increase in wall stress as a result of higher peak sys-
tolic pressure, among others, because of the premature
return of the reflected wave (quantitated as augmenta-
tion index). The latter is due to coronary underperfusion
from lower diastolic pressure since coronary perfusion of
occurs only during diastole.
NEW INSIGHTS INTO VASCULAR
CALCIFICATION IN UREMIA
In addition to the unquestionably deleterious role of
hyperphosphatemia, recent work identified osteogenic
differentiation of vascular smooth muscle cells (VSMC)
and dysregulations of calcification inhibitors, respec-
tively, as novel and potentially very important pathome-
chanisms in the development of vascular calcification.
Concerning osteogenic differentiation, groundbreak-
ing studies were performed by Giachelli’s group, pre-
senting evidence that hyperphosphatemia may not just
passively cause extraosseous calcification by causing
supersaturation of extracellular fluid for Ca × P. In
vitro studies performed in human VSMC demonstrated
that elevating phosphate concentration in the culture
medium from 1.4 to 2.0 mmol/L caused hydroxyapatite
formation, but more importantly, that this effect was
clearly dependent on a rise in the intracellular phosphate
concentration [45]. Blockade of the type III sodium-
phosphate-cotransporter Pit-1 by phosphonoformic acid
completely prevented calcification in this in vitro setting.
Moreover, this group observed the formation of ma-
trix vesicles, an up-regulation of the osteoblast transcrip-
tion factor core binding factor alpha-1 (cbfa-1) and de
novo expression of bone-related proteins, including alka-
line phosphatase, osteopontin, and osteocalcin by VSCM
under high phosphate conditions, while VSMC spe-
cific genes were consecutively down-regulated. Further-
more, monocyte- and macrophage-derived TNF-alpha
and oncostatin-M were also demonstrated to induce alka-
line phosphatase production and calcification in VSMC
in culture, implying that inflammation may as well be
involved in osteogenic differentiation processes in the
vessel wall [46]. The clinical relevance of these in vitro
observations was strongly supported by the immunohis-
tochemical detection of cbfa-1, alkaline phosphatase, and
osteopontin in calcified epigastric arteries of dialysis pa-
tients [47, 48].
Table 1. Calcification inhibitors and their potential relation to
extraosseous calcifications in chronic kidney disease (CKD)
Preliminary clinical data
Calcification
inhibitor Clinical relevance in CKD
Matrix GLA protein
(MGP)
Association with episodes of calciphylaxis
(CUA) due to suspected
undercarboxlyation and consecutive
inactivation of MGP [42–44]
Osteoprotegerin Increased OPG levels in hemodialysis
patients, positive association with aortic
calcifications; indicator of severity of
cardiovascular disease [47]
Fetuin-A Low fetuin-A levels are an
inflammation-related predictor of
all-cause and cardiovascular mortality in
dialysis patients [51], and are found in
patients with calciphylaxis (CUA) [5]
Pyrophosphates High bone pyrophosphate contents
correlate with soft-tissue calcification
[54]
THE ROLE OF CALCIFICATION INHIBITORS
It is important to be aware of the fact that even phys-
iologic serum concentrations of calcium and phosphate
clearly exceed the calcium-phosphate solubility product
by several orders of magnitude. It requires explanation
why immediate precipitation does not occur. In order to
control orthotopic and prevent continuous extraosseous
calcification, mammals obviously require a network of
more than 10 factors inhibiting calcification, as recently
reviewed elsewhere [49–51], 4 of which will be discussed
here in the context of chronic kidney disease (Table 1).
A novel understanding of the role of calcifica-
tion inhibitors was provided by transgenic calcification
inhibitor-deficient animals. The first example of such
an experimental approach was the creation of matrix
GLA protein knockout (MGP−/−) mice. MGP is a
10 kD Gla protein expressed in chondrocytes and VSMC.
MGP requires activation via vitamin K-dependent c-
carboxylation in order to act locally as a potent inhibitor
of cartilage and artery calcification [51, 52]. MGP−/− mice
develop excessive calcification of cartilage and of aortic
media predominantly of the elastic lamellae [51]. Aortic
calcification is associated with cartilagenous metaplasia
of the vessel wall. Animals die at 6 to 8 weeks of age from
aortic rupture (“fracture”). The vitamin K dependency
of MGP may be of relevance with regard to renal failure
patients. In patients with chronic kidney disease, a high
incidence of calciphylaxis (“calcific uremic arteriolopa-
thy,” CUA), a life-threatening exulcerating disease of the
skin characterized by pronounced small- and large-vessel
calcification, was observed in association with warfarin
treatment [53, 54]. Warfarin may well lead to deficient car-
boxylation of MGP, abrogating its ability to inhibit calcifi-
cation. This potential pathomechanism led the “Vascular
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Calcification Work Group” of the National Kidney Foun-
dation to consider recommendations to avoid uncritical
use of vitamin K antagonists in renal failure patients [55].
The osteoprotegerin (OPG)/receptor activator of
NFjB ligand (RANKL) system is another example of fac-
tors centrally involved in the regulation of bone turnover
and in calcification processes at extraosseous sites. OPG
is a secreted protein, and serves as a decoy receptor for
the OPG/RANKL system. It is another example of fac-
tors centrally involved simultaneously in the regulation
of bone turnover, and in calcification processes at ex-
traosseous sites. RANKL directly induces osteoclast dif-
ferentiation and maturation by RANK activation. As was
again demonstrated in transgenic animals, an excess of
RANKL causes severe osteoporosis, while an excess of
OPG leads to a cessation of bone turnover and consec-
utive osteopetrosis [56, 57]. In addition to osteoporosis,
OPG-deficient (OPG−/−) mice develop significant calci-
fication of aorta and renal arteries [56]. However, it is yet
unclear whether OPG deficiency contributes to vascular
calcification indirectly by providing increased amounts
of calcium and phosphate released from bone because
of increased osteoclastic bone degradation, or directly by
loss of the protein’s calcification inhibitory properties, re-
spectively. Nevertheless, the functional characteristics of
the OPG/RANKL system emphasize that there may be
an important link between bone loss and vascular calcifi-
cation, supporting the view that the bone’s function as a
“sponge” for calcium and phosphate may indeed be im-
portant to prevent progressive extraosseous calcification.
In this context, in their seminal communication, Braun
and Luft described in dialysis patients an inverse relation
between bone mineral density and coronary artery calcifi-
cation in dialysis patients [36]. However, the role of OPG
in renal failure patients is not yet solved. Nitta et al re-
cently reported that OPG levels were higher in hemodial-
ysis patients than in the normal population, and that high
OPG levels were independently associated with aortic
calcification, as shown by abdominal CT scans [58]. The
functional importance of these data is difficult to inter-
pret, since the related RANKL levels were not reported,
and since there is the possibility that OPG up-regulation
may act as an active, although perhaps incomplete, self-
defense mechanism to counteract excessive arterial cal-
cification. Thus, increased OPG levels may just serve as
an indicator of severe cardiovascular disease.
A third example of a clinically relevant calcification
inhibitor is fetuin-A, which is a major systemic and cir-
culating inhibitor of calcification accounting for approx-
imately 50% of the calcium and phosphate precipitation
inhibitory capacity of serum [59, 60]. Fetuin-A is syn-
thesized in the liver, reaches high extracellular concen-
trations (0.5–1.0 g/L), and, importantly, is regulated as a
negative acute-phase protein. Fetuin-A–deficient (fetuin-
A−/−) mice develop severe soft-tissue and parenchyma-
tous calcifications spontaneously or following challenges
with vitamin D or by feeding a mineral-rich diet, respec-
tively, depending on the genetic background of the mice
[60, 61]. Serum fetuin-A levels were found to be sig-
nificantly lower in both long- and short-term hemodial-
ysis patients when compared to controls with normal
renal function [62]. Moreover, the capacity to inhibit
precipitation of calcium and phosphate in the serum of
hemodialysis patients was significantly impaired, and this
was reversed by adding purified fetuin-A to the buffer
medium [62]. In a cross-sectional study including 312
hemodialysis patients, serum fetuin-A levels were in-
versely correlated with CRP levels. Fetuin-A deficiency
could be identified as an inflammation-related predictor
of mortality [62]. Although the phenotype of the fetuin-
A−/− mice is characterized by severe soft-tissue calcifi-
cations [61], suggesting that excess mortality in patients
with low serum fetuin-A levels may be directly related to
excessive extraosseous calcification, there is currently no
direct proof linking increased mortality and low fetuin-A
levels to overwhelming calcification. In addition, fetuin-A
deposition, but not local expression, is abundant in areas
of calcification (Fig. 3), potentially suggesting that fetuin-
A expression may be an initial, but exhaustible, attempt
to counteract extraosseous calcification. Future studies
will have to clarify whether fetuin-A deficiency indeed
predicts the calcification burden in ESRD patients.
As a final example of potentially important calci-
fication regulatory factors, pyrophosphates should be
mentioned. Some new light was recently shed on the
action of pyrophosphates by identifying a loss-of-function
mutation of the rate-limiting enzyme ectonucleotide
pyrophosphatase/phosphodiesterase-1 (ENPP-1) as the
central cause of idiopathic infantile arterial calcifica-
tion (IIAC), a rare and severe disease characterized by
calcified internal elastic laminae of arteries, and by my-
ointimal proliferation [63]. ANK is a multiple-pass trans-
membrane protein encoded by the progressive ankylosis
locus (ank), controlling pyrophosphate levels in tissues
by regulating their secretion. Mice deficient in this pro-
tein develop progressive periarticular calcification very
similar in their distribution to those not infrequently ob-
served in ESRD patients [64]. Pyrophosphates were long
known to possess crystal inhibitory or stabilizing proper-
ties, and were thought to be involved in the pathogenesis
of extraosseous calcification in uremia [65]. Nevertheless,
their exact role in this context has not been entirely clar-
ified and future studies are warranted. Lomashvilli et al
were recently able to demonstrate the crucial protective
role of pyrophosphates on injury- and phosphate-induced
calcification in a novel model using aortas from Sprague-
Dawley rats and osteopontin-deficient mice, respectively,
in vitro [66]. However, clear-cut clinical data on dysreg-
ulation or deficiency of pyrophosphates in the context of
uremic vascular calcification are still lacking.
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Fig. 3. Immunohistologic staining with anti-
body against fetuin (fetuin A, Bio Vendor
poly rabbit RD-346 Heidelberg, Germany, 1:
1000, light microscopy, magnification ×200).
(A) Coronary segment with marked staining
against fetuin in intima and media around an
atheromatous plaque. (B) A coronary seg-
ment of a patient with renal insufficiency with
very low staining of fetuin.
CONCLUSION
As indicated above, the list of potentially relevant cal-
cification inhibitors is already long [49–51], and the dis-
cussed factors are possibly only the “tip of an iceberg” of
an emerging concept, contributing a more sophisticated
explanation for the progressive nature of uremic vascular
disease. Based on such knowledge, it will be an important
challenge to develop new algorithms identifying patients
at highest risk for accelerated vascular calcification and
to develop new therapeutic strategies.
Reprint requests to Privatdozent Dr. med. Markus Ketteler, Medi-
zinische Klinik II: Nephrologie und klinische Immunologie, Univer-
sita¨tsklinikum Aachen, Pauwelsstr. 30, D 52057 Aachen, Germany.
E-mail: mketteler@ukaachen.de
REFERENCES
1. STANBURY SW, LUMB GA: Parathyroid function in chronic renal
failure. A statistical survey of the plasma biochemistry in azotaemic
renal osteodystrophy. Q J Med 35:1–23, 1966
2. NAVEH-MANY T, BELL O, SILVER J, KILAV R: Cis and trans acting
factors in the regulation of parathyroid hormone (PTH) mRNA
stability by calcium and phosphate. FEBS Lett 529:60–64, 2002
S-126 Ketteler et al: Hypertension and cardiovascular disease in progressive renal failure
3. MOZ Y, SILVER J, NAVEH-MANY T: Characterization of cis-acting ele-
ment in renal NaPi-2 cotransporter mRNA that determines mRNA
stability. Am J Physiol Renal Physiol 284:F663–670, 2003
4. NAVEH-MANY T, RAHAMIMOV R, LIVNI N, SILVER J: Parathyroid cell
proliferation in normal and chronic renal failure rats. The effects
of calcium, phosphate, and vitamin D. J Clin Invest 96:1786–1793,
1995
5. KROOK L: Dietary calcium-phosphorous and lameness in the horse.
Cornell Vet 58(Suppl):58–73, 1968
6. POND WG, TODD GC, DUNN JA, et al: A summary of observations
on control of atrophic rhinitis and virus pig pneumonia in swine. Vet
Med Small Anim Clin 62:67–72, 1967
7. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Associa-
tion of serum phosphorus and calcium × phosphate product with
mortality risk in chronic hemodialysis patients: A national study.
Am J Kidney Dis 31:607–617, 1998
8. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated
serum PO(4), Ca × PO(4) product, and parathyroid hormone with
cardiac mortality risk in chronic hemodialysis patients. J Am Soc
Nephrol 12:2131–2138, 2001
9. AMANN K, GROSS ML, LONDON GM, RITZ E: Hyperphos-
phataemia—A silent killer of patients with renal failure? Nephrol
Dial Transplant 14:2085–2087, 1999
10. AMANN K, TORNIG J, KUGEL B, et al: Hyperphosphatemia aggravates
cardiac fibrosis and microvascular disease in experimental uremia.
Kidney Int 63:1296–1301, 2003
11. GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiff-
ening and vascular calcifications in end-stage renal disease. Nephrol
Dial Transplant 15:1014–1021, 2000
12. ROSTAND SG, DRUEKE TB: Parathyroid hormone, vitamin D, and
cardiovascular disease in chronic renal failure. Kidney Int 56:383–
392, 1999
13. LONDON GM, PANNIER B, GUERIN AP, et al: Alterations of left ven-
tricular hypertrophy in and survival of patients receiving hemodialy-
sis: Follow-up of an interventional study. J Am Soc Nephrol 12:2759–
2767, 2001
14. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyper-
phosphatemia and hyperparathyroidism in dialysis patients: Rec-
ommendations for a change in management. Am J Kidney Dis
35:1226–1237, 2000
15. WEINREICH T, RAMBAUSEK M, RITZ E: Is control of secondary hy-
perparathyroidism optimal with the currently used calcium con-
centration in the CAPD fluid? Nephrol Dial Transplant 6:843–845,
1991
16. HSU CH: Are we mismanaging calcium and phosphate metabolism
in renal failure? Am J Kidney Dis 29:641–649, 1997
17. HOU SH, ZHAO J, ELLMAN CF, et al: Calcium and phosphorus fluxes
during hemodialysis with low calcium dialysate. Am J Kidney Dis
18:217–224, 1991
18. ZUCCHELLI P, SANTORO A: Inorganic phosphate removal during dif-
ferent dialytic procedures. Int J Artif Organs 10:173–178, 1987
19. MUCSI I, HERCZ G, ULDALL R, et al: Control of serum phosphate
without any phosphate binders in patients treated with nocturnal
hemodialysis. Kidney Int 53:1399–1404, 1998
20. ABBOTT KC, GLANTON CW, TRESPALACIOS FC, et al: Body mass in-
dex, dialysis modality, and survival: Analysis of the United States
Renal Data System Dialysis Morbidity and Mortality Wave II Study.
Kidney Int 65:597–605, 2004
21. PORT FK, ASHBY VB, DHINGRA RK, et al: Dialysis dose and body
mass index are strongly associated with survival in hemodialysis
patients. J Am Soc Nephrol 13:1061–1066, 2002
22. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery cal-
cification in young adults with end-stage renal disease who are un-
dergoing dialysis. N Engl J Med 342:1478–1483, 2000
23. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the pro-
gression of coronary and aortic calcification in hemodialysis pa-
tients. Kidney Int 62:245–252, 2002
24. TAMASHIRO M, ISEKI K, SUNAGAWA O, et al: Significant association
between the progression of coronary artery calcification and dys-
lipidemia in patients on chronic hemodialysis. Am J Kidney Dis
38:64–69, 2001
25. JOY MS, FINN WF: Randomized, double-blind, placebo-controlled,
dose-titration, phase III study assessing the efficacy and tolerability
of lanthanum carbonate: A new phosphate binder for the treatment
of hyperphosphatemia. Am J Kidney Dis 42:96–107, 2003
26. D’HAESE PC, SPASOVSKI GB, SIKOLE A, et al: A multicenter study
on the effects of lanthanum carbonate (Fosrenol) and calcium car-
bonate on renal bone disease in dialysis patients. Kidney Int (Suppl
85):S73–S78, 2003
27. BEHETS GJ, VERBERCKMOES SC, D’HAESE PC, DE BROE ME: Lan-
thanum carbonate: A new phosphate binder. Curr Opin Nephrol
Hypertens 13:403–409, 2004
28. BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al: Cinacalcet for sec-
ondary hyperparathyroidism in patients receiving hemodialysis. N
Engl J Med 350:1516–1525, 2004
29. STEVENS LA, DJURDJEV O, CARDEW S, et al: Calcium, phosphate,
and parathyroid hormone levels in combination and as a function
of dialysis duration predict mortality: Evidence for the complexity
of the association between mineral metabolism and outcomes. J Am
Soc Nephrol 15:770–779, 2004
30. LONDON GM, MARTY C, MARCHAIS SJ, et al: Arterial calcifications
and bone histomorphometry in end-stage renal disease. J Am Soc
Nephrol 15:1943–1951, 2004
31. SCHWARZ U, BUZELLO M, RITZ E, et al: Morphology of coronary
atherosclerotic lesions in patients with end-stage renal failure.
Nephrol Dial Transplant 15:218–223, 2000
32. FUESSL RT, KRANENBERG E, KIAUSCH U, et al: Vascular remodeling in
atherosclerotic coronary arteries is affected by plaque composition.
Coron Artery Dis 12:91–97, 2001
33. OH J, WUNSCH R, TURZER M, et al: Advanced coronary and carotid
arteriopathy in young adults with childhood-onset chronic renal
failure. Circulation 106:100–105, 2002
34. STEFENELLI T, ABELA C, FRANK H, et al: Cardiac abnormalities in
patients with primary hyperparathyroidism: Implications for follow-
up. J Clin Endocrinol Metab 82:106–112, 1997
35. HEDBACK G, ODEN A: Increased risk of death from primary
hyperparathyroidism—An update. Eur J Clin Invest 28:271–276,
1998
36. BRAUN J, OLDENDORF M, MOSHAGE W, et al: Electron beam com-
puted tomography in the evaluation of cardiac calcification in
chronic dialysis patients. Am J Kidney Dis 27:394–401, 1996
37. GOODMAN WG, LONDON G, AMANN K, et al: Vascular calcification
in chronic kidney disease. Am J Kidney Dis 43:572–579, 2004
38. RAGGI P, BOULAY A, CHASAN-TABER S, et al: Cardiac calcification in
adult hemodialysis patients. A link between end-stage renal disease
and cardiovascular disease? J Am Coll Cardiol 39:695–701, 2002
39. BURSZTYN M, MOTRO M, GROSSMAN E, SHEMESH J: Accelerated coro-
nary artery calcification in mildly reduced renal function of high-
risk hypertensives: A 3-year prospective observation. J Hypertens
21:1953–1959, 2003
40. KEELAN PC, BIELAK LF, ASHAI K, et al: Long-term prognostic value
of coronary calcification detected by electron-beam computed to-
mography in patients undergoing coronary angiography. Circulation
104:412–417, 2001
41. MATSUOKA M, ISEKI K, TAMASHIRO M, et al: Impact of high coronary
artery calcification score (CACS) on survival in patients on chronic
hemodialysis. Clin Exp Nephrol 8:54–58, 2004
42. LONDON GM, GUERIN AP, MARCHAIS SJ, et al: Arterial media calci-
fication in end-stage renal disease: Impact on all-cause and cardio-
vascular mortality. Nephrol Dial Transplant 18:1731–1740, 2003
43. WANG AY, WANG M, WOO J, et al: Cardiac valve calcification as
an important predictor for all-cause mortality and cardiovascular
mortality in long-term peritoneal dialysis patients: A prospective
study. J Am Soc Nephrol 14:159–168, 2003
44. AMANN K, WOLF B, NICHOLS C, et al: Aortic changes in experimental
renal failure: Hyperplasia or hypertrophy of smooth muscle cells?
Hypertension 29:770–775, 1997
45. JONO S, MCKEE MD, MURRY CE, et al: Phosphate regulation of
vascular smooth muscle cell calcification. Circ Res 87:E10–17, 2000
46. TINTUT Y, PATEL J, TERRITO M, et al: Monocyte/macrophage reg-
ulation of vascular calcification in vitro. Circulation 105:650–665,
2002
47. MOE SM, O’NEILL KD, DUAN D, et al: Medial artery calcification
in ESRD patients is associated with deposition of bone matrix pro-
teins. Kidney Int 61:638–647, 2002
48. MOE SM, DUAN D, DOEHLE BP, O’NEILL KD, CHEN NX: Uremia
Ketteler et al: Hypertension and cardiovascular disease in progressive renal failure S-127
induces the osteoblast differentiation factor Cbfa1 in human blood
vessels. Kidney Int 63:1003–1011, 2003
49. FARZANEH-FAR A, PROUDFOOT D, SHANAHAN C, WEISSBERG PL: Vas-
cular and valvar calcifications: Recent advances. Heart 85:13–17,
2001
50. KETTELER M, WANNER C, METZGER T, et al: Deficiencies of calcium-
regulatory proteins in dialysis patients: A novel concept of car-
diovascular calcification in uremia. Kidney Int (Suppl 84):S84–S87,
2003
51. VATTIKUTI R, TOWLER DA: Osteogenic regulation of vascular cal-
cification: An early perspective. Am J Physiol Endocrinol Metab
286:E686–E696, 2004
52. LUO G, DUCY P, MCKEE MD, et al: Spontaneous calcification of
arteries and cartilage in mice lacking matrix GLA protein. Nature
386:78–81, 1997
53. Case Records of the Massachussets General Hospital. New Engl J
Med 345:1119–1124, 2001
54. COATES T, KIRKLAND GS, DYMOCK RB, et al: Cutaneous necrosis
from calcific uremic arteriolopathy. Am J Kidney Dis 32:384–391,
1998
55. GOODMAN WG, LONDON G, AMANN K, et al: Vascular Calcification
Work Group: Vascular calcification in chronic kidney disease. Am
J Kidney Dis 43:572–579, 2004
56. BUCAY N, SAROSI I, DUNSTAN CR, et al: Osteoprotegerin-deficient
mice develop early onset osteoporosis and arterial calcification.
Genes Dev 12:1260–1268, 1998
57. SIMONET WS, LACEY DL, DUNSTAN CR, et al: Osteoprotegerin: A
novel secreted protein involved in the regulation of bone density.
Cell 89:309–319, 1997
58. NITTA K, AKIBA T, UCHIDA K, et al: The progression of vascular
calcification and serum osteoprotegerin levels in patients on long-
term hemodialysis. Am J Kidney Dis 42:303–309, 2003
59. SCHINKE T, AMENDT C, TRINDL A, et al: The serum protein alpha2-
HS glycoprotein/fetuin inhibits apatite formation in vitro and in
mineralizing calvaria cells. A possible role in mineralization and
calcium homeostasis. J Biol Chem 271:20789–20796, 1996
60. JAHNEN-DECHENT W, SCHINKE T, TRINDL A, et al: Cloning and tar-
geted deletion of the mouse fetuin gene. J Biol Chem 272:31496–
31503, 1997
61. SCHAFER C, HEISS A, SCHWARZ A, et al: The serum protein alpha
2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting
inhibitor of ectopic calcification. J Clin Invest 112:357–366, 2003
62. KETTELER M, BONGARTZ P, WESTENFELD R, et al: Association of
low fetuin-A (AHSG) concentrations in serum with cardiovascu-
lar mortality in patients on dialysis: A cross-sectional study. Lancet
361:827–833, 2003
63. RUTSCH F, RUF N, VAINGANKAR S, et al: Mutations in ENPP1 are
associated with ‘idiopathic’ infantile arterial calcification. Nat Genet
34:379–381, 2003
64. HO AM, JOHNSON MD, KINGSLEY DM: Role of the mouse ank gene
in control of tissue calcification and arthritis. Science 289:265–270,
2000
65. ALFREY AC, SOLOMONS CC: Bone pyrophosphate in uremia and its
association with extraosseous calcification. J Clin Invest 57:700–705,
1976
66. LOMASHVILLI KA, COBBS S, HENNIGAR RA, et al: Phosphate-induced
vascular calcification: Role of pyrophosphate and osteopontin. J Am
Soc Nephrol 15:1392–1401, 2004
